Showing results (111-120 of 153) with videos related to

Sort By:
Pageof 16
Equine Veterinary Journal|August 23, 2019
Chlamydia psittaci infection as a cause of respiratory disease in neonatal foalsS L Gough, J Carrick, S L Raidal, et al.
The Journal of Clinical Endocrinology and Metabolism|December 8, 2004
Common allelic variants of exons 10, 12, and 33 of the thyroglobulin gene are not associated with autoimmune thyroid disease in the United KingdomJ E Collins, J M Heward, J M M Howson, et al.
Clinical Endocrinology|March 21, 2007
Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves' disease using a multilocus test and tag SNPsOliver J Brand, Christopher E Lowe, Joanne M Heward, et al.
Diabetes, Obesity & Metabolism|May 19, 2015
One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trialS C L Gough, B W Bode, V C Woo, et al.
The Journal of Clinical Endocrinology and Metabolism|February 7, 2013
Inhibition of islet immunoreactivity by adiponectin is attenuated in human type 1 diabetesTerence T L Pang, Myriam Chimen, Edward Goble, et al.
Human Molecular Genetics|June 29, 2007
A novel and major association of HLA-C in Graves' disease that eclipses the classical HLA-DRB1 effectMatthew J Simmonds, Joanna M M Howson, Joanne M Heward, et al.
Genes and Immunity|May 2, 2008
Analysis of HLA class II genes in Hashimoto's thyroiditis reveals differences compared to Graves' diseaseA A Zeitlin, J M Heward, P R Newby, et al.
Clinical Endocrinology|February 13, 2010
Association of FcGRIIa with Graves' disease: a potential role for dysregulated autoantibody clearance in disease onset/progressionKadija Yesmin, Chantal Hargreaves, Paul R Newby, et al.
Clinical Endocrinology|May 11, 2007
Tag SNP screening of the PDCD1 gene for association with Graves' diseaseP R Newby, E L Roberts-Davies, O J Brand, et al.
Diabetes Care|January 24, 2013
The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetesLuigi Meneghini, Stephen L Atkin, Stephen C L Gough, et al.
Pageof 16